Mostrar el registro sencillo del ítem

dc.contributor.authorRodríguez-Carrio, Javier
dc.contributor.authorCerro-Pardo, Isabel
dc.contributor.authorLindholt, Jes S
dc.contributor.authorBonzon-Kulichenko, Elena 
dc.contributor.authorMartínez-López, Diego
dc.contributor.authorRoldán-Montero, Raquel
dc.contributor.authorEscolà-Gil, Joan-Carles
dc.contributor.authorMichel, Jean-Baptiste
dc.contributor.authorBlanco-Colio, Luis Miguel
dc.contributor.authorVazquez, Jesus 
dc.contributor.authorSuárez, Ana
dc.contributor.authorMartín-Ventura, José Luis
dc.date.accessioned2024-06-27T10:19:31Z
dc.date.available2024-06-27T10:19:31Z
dc.date.issued2021-10
dc.identifier.citationFree Radic Biol Med. 2021 Oct:174:171-181.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19880
dc.description.abstractHigh Density Lipoprotein (HDL) plays a protective role in abdominal aortic aneurysm (AAA); however, recent findings suggest that oxidative modifications could lead to dysfunctional HDL in AAA. This study aimed at testing the effect of oxidized HDL on aortic lesions and humoral immune responses in a mouse model of AAA induced by elastase, and evaluating whether antibodies against modified HDL can be found in AAA patients. HDL particles were oxidized with malondialdehyde (HDL-MDA) and the changes were studied by biochemical and proteomics approaches. Experimental AAA was induced in mice by elastase perfusion and then mice were treated with HDL-MDA, HDL or vehicle for 14 days. Aortic lesions were studied by histomorphometric analysis. Levels of anti-HDL-MDA IgG antibodies were measured by an in-house immunoassay in the mouse model, in human tissue-supernatants and in plasma samples from the VIVA cohort. HDL oxidation with MDA was confirmed by enhanced susceptibility to diene formation. Proteomics demonstrated the presence of MDA adducts on Lysine residues of HDL proteins, mainly ApoA-I. MDA-modification of HDL abrogated the protective effect of HDL on cultured endothelial cells as well as on AAA dilation in mice. Exposure to HDL-MDA elicited an anti-HDL-MDA IgG response in mice. Anti-HDL-MDA were also detected in tissue-conditioned media from AAA patients, mainly in intraluminal thrombus. Higher plasma levels of anti-HDL-MDA IgG antibodies were found in AAA patients compared to controls. Anti-HDL-MDA levels were associated with smoking and were independent predictors of overall mortality in AAA patients. Overall, MDA-oxidized HDL trigger a specific humoral immune response in mice. Besides, antibodies against HDL-MDA can be detected in tissue and plasma of AAA patients, suggesting its potential use as surrogate stable biomarkers of oxidative stress in AAA.es_ES
dc.description.sponsorshipThis study was funded by the Spanish MINECO (SAF2016-80843-R, PID2019-106814RB-I00 and PGC2018-097019-B-I00), CAM (Complemento II-CM, S2017/BMD-3673), Fondo de Investigaciones Sanitarias ISCIII-FEDER (PI19/00128, Biobancos RD09/0076/00101, PI16/ 00113 and PT17/0019/0003-ISCIII-SGEFI/ERDF, ProteoRed), and FEDER “Una manera de hacer Europa”. CIBERCV and CIBERDEM are Instituto de Salud Carlos III projects. The work leading to these results has also received funding from “la Caixa” Banking Foundation under the project code HR17-00247.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAortic Aneurysm, Abdominal es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshEndothelial Cells es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunoglobulin G es_ES
dc.subject.meshLipoproteins, HDL es_ES
dc.subject.meshMalondialdehyde es_ES
dc.subject.meshMice es_ES
dc.subject.meshMice, Inbred C57BL es_ES
dc.titleMalondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID34364980es_ES
dc.format.volume174es_ES
dc.format.page171es_ES
dc.identifier.doi10.1016/j.freeradbiomed.2021.08.004es_ES
dc.contributor.funderMinisterio de Economía, Innovación y Competitividad (España) es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderFundación La Caixa es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1873-4596es_ES
dc.relation.publisherversion10.1016/j.freeradbiomed.2021.08.004es_ES
dc.identifier.journalFree radical biology & medicinees_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Proteómica / Metabolómicaes_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SAF2016-80843-Res_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-106814RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PGC2018-097019-B-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/S2017/BMD-3673es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PT17/0019/0003-ISCIII-SGEFI/ERDFes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/HR17-00247es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional